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Abstract
Background: The signaling pathways that may modulate the pathogenesis of diseases induced by expanded polyglutamine
proteins are not well understood.
Methodologies/Principal Findings: Herein we demonstrate that expanded polyglutamine protein cytotoxicity is mediated
primarily through activation of p38MAPK and that the atypical PKC iota (PKCi) enzyme antagonizes polyglutamine-induced
cell death through induction of the ERK signaling pathway. We show that pharmacological blockade of p38MAPK rescues
cells from polyglutamine-induced cell death whereas inhibition of ERK recapitulates the sensitivity observed in cells
depleted of PKCi by RNA interference. We provide evidence that two unrelated proteins with expanded polyglutamine
repeats induce p38MAPK in cultured cells, and demonstrate induction of p38MAPK in an in vivo model of
neurodegeneration (spinocerebellar ataxia 1, or SCA-1).
Conclusions/Significance: Taken together, our data implicate activated p38MAPK in disease progression and suggest that
its inhibition may represent a rational strategy for therapeutic intervention in the polyglutamine disorders.
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Introduction
The polyglutamine diseases encompass at least 9 different
disorders including Huntington’s disease (HD) and five spinocer-
ebellar ataxias (SCA-1, SCA-2, SCA-3, SCA-6 and SCA-7
(reviewed in [1]). These are dominantly inherited diseases typically
detected in the third or fourth decade of life. No effective
therapeutic interventions are currently available, and the polyglu-
tamine diseases are generally fatal. Polyglutamine disorders arise
from expansion of a CAG repeat within the coding region of genes
such that the length of the encoded polyglutamine stretch exceeds
a critical threshold. At the ultrastructural level, disease progression
features heat shock protein (HSP)-containing nuclear ubiquiti-
nated inclusions [2] that have accumulated an assortment of
cellular host components in association with the polyglutamine-
containing protein [3]. There is evidence from experiments
performed in cultured mammalian cells and animal models of
disease that polyglutamine expanded proteins adversely affect
basic biological processes (reviewed in [4]). Their expression has
been associated with impaired proteolysis [5], loss of transcrip-
tional control mechanisms [6] and with altered regulation of cell
death/survival pathways (reviewed in [7]).
The mitogen-activated protein kinases (MAPK) are involved in
the integration and processing of multiple extracellular signals and
their induction triggers diverse biological responses (reviewed in
[8,9]). While the activation of the extracellular regulated kinase 1/
2 (hereafter referred to as ERK) by mitogenic and proliferative
stimuli is coupled to cell survival [10], stress inducible kinases JNK
and p38MAPK respond to environmental stress and their
sustained activation transduces signals leading to cell death
(reviewed in [11]). Protein kinase C (PKCs) family members have
been positioned upstream of ERK and are potent modulators of its
activation (reviewed in [12]). With the current exception of the
stress-inducible kinase JNK whose excessive activation has been
well documented in neurodegenerative diseases [13] and reviewed
in [14], the mechanistic relationship between the stress inducible
host signaling pathways and expanded polyglutamine-induced
toxicity remain controversial. It has been shown, for example, that
the mutant huntingtin (Htt) protein causes aberrant activation of
epidermal growth factor receptor (EGFR) signaling [15], a finding
which has been contradicted by more recent reports in which
EGFR signaling was disrupted by expression of the expanded
polyglutamine protein [16,17]. In a Drosophila model of polyglu-
tamine toxicity, the mutant Htt protein has been shown to disrupt
EGFR signaling through interference with the ERK cascade [18]
while in a cell culture model it has been shown to activate the pro-
survival pathway mediated through ERK [19]. All these anomalies
are consistent with gain of function effects of expanded
polyglutamine proteins. There is ample evidence from experi-
mental systems that a simple polyglutamine tract can be toxic
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[20,21] but possible loss of function effects in polyglutamine
proteins must also be considered. The normal huntingtin protein,
for example, has been shown to increase transcription of brain-
derived neurotrophic factor (BDNF), which is required for survival
of striatal neurons [22,23]. Loss of this activity in the mutant
protein may therefore contribute to neuronal loss in diseased
individuals. Insulin-like growth factor I also has neuroprotective
activity in the context of polyglutamine-induced cytotoxicity
[24,25], and like BDNF activates the survival pathway mediated
through the phosphoinositide 3-kinase (PI3-K) [26–28]. Kinases
activated downstream in this pathway include PKB/Akt and the
atypical protein kinase C iota (PKCi) [29,30,31–34]. The toxicities
of huntingtin and ataxin-1 gene products are modulated by their
phosphorylation states [35,36], but while the role of PKB/Akt
activity has been studied in this context nothing is known of the
role of PKCi.
As a starting point the current study sought to address the role
of MAPK signaling pathways in polyglutamine disorders including
Huntington’s disease and SCA-1. Our findings suggest that
expanded polyglutamine proteins mediate adverse effects through
activation of p38MAPK signaling and that this cytotoxicity is
antagonized by PKCi, which enhances protective signaling
through the ERK pathway. We show that pharmacological
inhibition of p38MAPK rescues cells from polyglutamine-induced
cell death whereas inhibition of ERK signaling or depletion of
PKCi by RNA interference enhances cytotoxicity.
Methods
Reagents and antibodies
Custom RNA interference duplexes were synthesized by
Dharmacon RNA Technologies Inc. (Lafayette, CO, USA). A
control duplex having the following sense RNA sequence
AUUCUAUCACUAGCGUGACUU (non-specific control du-
plex) was purchased from Dharmacon Research, Inc and used as a
control. RNA duplex concentrations were determined by
measuring absorbance at 260 nm and calculating concentrations
using extinction coefficients provided by the manufacturer.
Propidium iodide and MTT reagents were purchased from
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). P38MAPK
inhibitors, SKF86002 and SB202190 were purchased from
Calbiochem (San Diego, CA, USA) and Biosource (Camarillo,
CA, USA) respectively. The MEK inhibitor U0126 was from
Promega (Madison, WI, USA). The goat polyclonal antibodies
nPKCæ (used to detect PKCi) and ataxin-1 were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). The mouse
monoclonal phospho-p38MAPK and phospho-ERK 1/2 antibod-
ies and the rabbit polyclonal p38MAPK antibody were from Cell
Signaling Technology (Beverly, MA, USA). Pan ERK monoclonal
antibody was from Transduction Laboratories (Lexington, KY,
USA). GFP, Htt-25 and Htt-103 were detected with a mouse
monoclonal AFP antibody purchased from Quantum Biotechnol-
ogies Inc.(Montre ´al, Que ´bec, Canada). Phospho-ATF2 and total
ATF2 levels were detected with rabbit polyclonal antibodies
purchased from Cell Signaling Technology (Beverly, MA, USA).
The mouse monoclonal actin antibody was purchased from
Sigma-Aldrich Canada (Oakville, ON).
Expression constructs and transgenic mice
The pEGFP-N1 expression construct which served as a control
in transient transfection experiments was purchased from
Clontech (Palo Alto, California, USA). The Htt-25 and Htt-103
expression constructs (gifts from Dr. Ron Kopito) contain a
synthetic insert encoding exon 1 of human Huntingtin containing
a polyglutamine tract of either 25Q or 103Q fused to the yellow
fluorescent reporter protein (YFP). The plasmids encoding the full
length human ataxin-1 proteins with a polyglutamine tract of 30Q
or 83Q were a gift from Dr. Huda Zoghbi. The origin of the B05
transgenic line carrying a mutant Ataxin-1 allele with 82 CAG
repeats and the A02 line with a CAG repeat of 30 codons was
described in a paper from the laboratory of Dr. Harry Orr [37],
from whom these lines were obtained.
Cell culture and transfections
The human U87MG cell line (a gift from Dr. W. Cavenee,
Ludwig Institute for Cancer Research, La Jolla, CA) was
maintained at 37uC and 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 100 units/ml penicillin,
100 mg/ml streptomycin, 2 mM glutamine and 10% (v/v) of a 2:1
mixture of donor bovine serum and fetal bovine serum. For RNA
interference experiments, cells were transfected using Oligofecta-
mine (Invitrogen Canada, Inc., Burlington, ON) as per the
supplier’s protocol. Final concentrations of RNA in the transfec-
tions were 5.3 nM for siPKCiA and 20 nM for siPKCiB. Control
RNA concentrations were matched to the specific siRNA duplex
used in the experiment. For transient transfections, cells were
plated in either 96- or 6 well dishes 24 hours prior to transfections.
Subsequently, they were transfected using GeneJuice Transfection
Reagent (Novagen, Madison, WI, USA) as per the supplier’s
protocol. 0.5 mg of plasmid DNA was used in each well of a 96
well dish. A total amount of 3 mg of plasmid DNA was used in
each well of a 6 well dish. For p38MAPK inhibition experiments
using SKF86002 and SB202190, cells in 96 well plates were
transfected with RNA duplexes. 24 hours post-transfection, cells
were pre-treated for 2 h with 20 mM of the respective inhibitor.
ERK inhibition experiments were performed in a similar manner
using the MEK inhibitor U0126 at a final concentration of
20 mM. Following this incubation period cells were transiently
transfected with various expression constructs.
Survival assays
Survival assays were performed by MTT, trypan blue exclusion
and flow cytometry. For MTT assays, cells in 96 well microtitre
plates were transfected with RNA duplexes as described above.
6 h post-transfection, they were transiently transfected with the
GFP control vector, Htt-25, Htt-103, Atx-30 or Atx-83 as
indicated. 24 h post-transfection of the plasmid DNA cell survival
was assessed using the MTT (3-(4,5-cimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay as described previously
[38]. Background values were determined by carrying out the
assay in wells containing media without cells. Toxicity was
measured by trypan blue exclusion in pooled fractions consisting
of attached and detached cells. For flow cytometry experiments,
adherent and non-adherent cells were harvested and fixed with
70% (v/v) ethanol in PBS. Cell nuclei were stained with propidium
iodide. DNA content was analyzed by flow cytometry using a BD
LSR flow cytometer (Becton Dickinson, San Jose, CA). Data was
acquired using Cell Quest software (Becton Dickinson, San Jose,
CA) and were analyzed using Mod Fit LT software (Verity
Software House, Inc., Sopsham, ME).
Western blot analysis
U87MG cells were harvested in protein lysis buffer consisting of
100 mM Tris pH 6.8, 20 mM DTT, 4% SDS, 5% glycerol.
Protein concentrations were determined using the Bradford assay
reagents (Bio-Rad, Hercules, CA, USA). Reduced proteins were
separated through 4–12% bis-tris polyacrylamide gels using an
p38MAPK in polyQ Toxicity
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Proteins were transferred onto PVDF nylon membranes (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK) and stained with
amido black prior to probing with the appropriate primary
antibody. Proteins were detected using the HRP method and
SuperSignal West Pico Chemiluminescent Substrate reagents
(Pierce, Rockford, IL, USA). Proteins were visualized using the
GeneGnome (Syngene, Frederick, MD,USA). Sequential probing
of membranes was performed after stripping with the use of
Western Blot Stripping Buffer (Pierce, Rockford, IL, USA) for
30 min at room temperature. Mouse cerebella were harvested by
homogenization in protein lysis buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.5 mM EDTA, 1% NP-40 and 20% glycerol)
containing the following protease and phosphatase inhibitors:
200 mg/ml phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin,
2 mg/ml aprotinin, 200 mM NaF, 200 mM NaPPi and 10 mM
NEM. Soluble protein was quantified as described above. Proteins
were resolved on a 10% SDS-polyacrylamide gel and electro-
blotted onto a Hybond C nitrocellulose membrane (Amersham
Biosciences Corp, Baie d’Urfe ´, QC). The membranes were stained
with Ponceau S prior to immunoblotting with the appropriate
primary antibody. Proteins were visualized as described above.
Immunohistochemistry
Cerebella from age-matched nontransgenic, A02 and B05 mice
were excised and fixed in 10% phosphate-buffered formalin
overnight at room temperature. Tissues were paraffin-embedded
and sectioned sagitally using a microtome at a thickness of 5 mm.
Deparaffinized sections were heated in a solution of 10 mM
sodium citrate (pH 6.0) in 700W microwave for 10 minutes.
Endogenous peroxidase activity was blocked by incubating in
methanol containing 3% hydrogen peroxide for 20 minutes.
Sections were washed with PBS (pH 7.4) and incubated for
30 minutes with 1.5% normal goat serum (Santa Cruz Biotech-
nologies Inc., SC, CA, USA) to block nonspecific binding. Sections
were then incubated overnight at 4uC with the phospho-
p38MAPK antibody (Cell Signaling Technology, Beverly, MA,
USA). The reaction product was visualized with the ABC system
(DAKO Diagnostics Canada Inc.). The use of animals in these
experiments followed the guidelines of the Animal Care
Committee of the University of Ottawa and was approved under
protocol number ME-212.
Statistical analysis
Unless otherwise indicated, all values are represented as the
average of three independent experiments performed in triplicate,
with error bars indicating standard error of the mean. Statistical
significance was determined by a two tailed Student’s t-test. Values
were considered significant when P,0.05.
Results
PKCi modulates the sensitivity of cells to polyglutamine-
induced cellular death
We used a previously described siRNA strategy [38] to
investigate the role of PKCi depletion in polyglutamine-induced
cytotoxicity. This method specifically depletes PKCi RNA and
protein with no effect on other PKC enzymes [38]. We used
U87MG cells which have been shown to have an elevated basal
ERK activity as a result of increased signaling through the EGFR
pathway [39]. We reasoned that if ERK was protective such a cell
model would be less sensitive to expanded polyglutamine induced
toxicity. The use of cells from a glial as opposed to neuronal
lineage is unlikely to be of consequence in that similar results were
obtained in glioblastoma and neuroblastoma cell lines (as
described below). To assess whether the depletion of PKCi would
affect cell survival in the presence of an expanded polyglutamine
protein, U87MG cells were transfected with a control or one of
two siPKCi RNAs (siPKCiA and siPKCiB). Cells were then
transiently transfected with either a GFP control plasmid or
constructs encoding exon 1 of the Huntingtin protein containing a
normal polyglutamine tract of 25Qs (hereafter referred to as Htt-
25) or with a pathogenic tract of 103Qs (hereafter referred to as
Htt-103) fused to the yellow fluorescent protein (YFP) reporter.
Similar expression constructs encoding exon 1 of the Htt protein
with an expanded polyglutamine tract have been previously used
in cell culture models of polyglutamine toxicity [6,40] and in the
generation of the well characterized R6/2 transgenic mouse line
[41]; R6/2 mice develop a progressive neurological phenotype
with motor symptoms resembling those in HD [42]. By phase
contrast microscopy, a pronounced effect was observed in PKCi
depleted cells expressing Htt-103 wherein a significant increase in
the number of shrunken, rounded and detached cells was noted
(Figure 1A). Analogous to other cell culture systems used in the
study of polyglutamine biology (3T3, PC12, SHY-5Y cells, etc),
U87MG cells expressing Htt-103 were found to accumulate visible
nuclear inclusions as early as 24 hours post-transfection
(Figure 1B). No such inclusions were observed in cells expressing
GFP alone or Htt-25 (Figure 1B). Depletion of PKCi was assessed
by Western blot analysis with an antibody recognizing PKCi in
extracts from U87MG cells transfected with either the control or
siPKCiA and siPKCiB; a reduction in the protein levels was
observed at 24 and 48 hours post-transfection (Figure 1C). The
transfection efficiency of the Htt proteins in U87MG cells was
estimated at ,80% as assessed by fluorescence microscopy
(Figure 1B). Similar levels of expression of GFP, Htt-25 and Htt-
103 were confirmed by Western blot analysis of extracts from
transfected cells with an antibody specific for the fluorescent
protein reporter (Figure 1D). Quantification of survival with the
use of a metabolic assay (MTT) revealed that the depletion of
PKCi sensitized cells to the expression of Htt-103 such that
survival was reduced by approximately 25% when compared to
cells transfected with the control RNA (Figure 2B). The survival of
U87MG cells transfected with an Htt-25 expression plasmid was
no different then that of cells expressing GFP alone (Figure 2A).
When compared to GFP transfectants, the depletion of PKCi
mildly sensitized cells to the expression of Htt-25 but to a lesser
extent than did expression of Htt-103 (Figure 2A and B). The data
obtained by MTT analysis were consistent with survival as
measured by the trypan-blue exclusion method (Figure 2C) and by
flow cytometric analysis (Figure 2D) of Htt-103 transfected cells,
both of which revealed an increase in cell death in PKCi depleted
cells when compared to control RNA transfectants. These data
suggested that the depletion of PKCi was sensitizing cells to the
expression of expanded polyglutamine proteins. As assessed by
MTT, the exogenous expression of flag-tagged PKCi was found to
modestly increase the resistance of cells to the toxic effects
associated with expression of Htt-103 (Figure 2E). The overex-
pression of PKCi in these stable transfectants was confirmed by
Western blot analysis with both the PKCi and flag tag antibodies
respectively (Figure 2F).
Impaired ERK activation sensitizes cells to polyglutamine-
expanded proteins
It has been previously reported that PKCi is positioned
upstream of the mitogen-regulated kinase ERK [43] and it was
therefore conceivable that PKCi depletion would affect ERK
activation. To test this hypothesis, we examined the basal levels of
p38MAPK in polyQ Toxicity
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or siPKCiA RNA transfected cells were analyzed by Western blot
analysis with an antibody recognizing phospho-ERK. The analysis
revealed a reduction in ERK phosphorylation in PKCi depleted
cells when compared to the levels in U87MG cells transfected with
the control RNA (Figure 3A). These data suggested that U87MG
cells have elevated basal levels of activated ERK most probably
due to the constitutively active EGFR pathway and that PKCi
depletion affects ERK induction. To investigate specifically
whether the loss of ERK signaling due to PKCi depletion was
the basis for the increased sensitivity observed in PKCi depleted
cells to expanded polyglutamine protein expression, we made use
Figure 1. Morphological alterations in PKCi depleted cells expressing Htt-103. A) U87MG cells transfected with the control or with siPKCiA
and siPKCiB were transiently transfected with plasmids encoding GFP, Htt-25 or Htt-103 for 24 hours. Cell morphology was assessed by phase
contrast microscopy. An increase in the number of shrunken, rounded and detached cells was observed in PKCi depleted cells expressing Htt-103
when compared to control RNA transfected cells or cells expressing GFP or Htt-25. Magnification was 406. B) U87MG cells expressing GFP, Htt-25 or
Htt-103 for 24 hours were visualized under fluorescence (bottom panel) to assess transfection efficiency. Upper panels represent the same field of
view visualized under white light. Arrowheads demonstrate nuclear inclusions in Htt-103 expressing cells. Scale bars represent 100 mm. C) Western
blot analysis with a PKCi specific antibody of cell extracts from U87MG cells transfected in duplicate with either the control or siPKCiA and siPKCiB
showing the reduction in the protein levels of PKCi at 24 and 48 hours post-transfection. The membrane was re-probed with an antibody directed
against Pan-ERK which served as a loading control. D) Western blot analysis of cell extracts from cells transfected with either control or siPKCiA
expressing GFP, Htt-25 or Htt-103 with an antibody raised against AFP. No significant difference in the protein levels of GFP, Htt-25 and Htt-103 were
observed in extracts from control and PKCi transfected cells. The membrane was re-probed with an antibody directed against Pan-ERK which served
as a loading control.
doi:10.1371/journal.pone.0002130.g001
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PLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2130Figure 2. Depletion of PKCi sensitizes cells to polyglutamine induced toxicity. A) and B) U87MG cells transfected for 24 hours with either
control or siPKCiA and PKCiB were plated in 96 well dishes. Subsequently, cells were transfected with expression constructs encoding GFP, Htt-25 (A)
and Htt-103 (B) and cell survival was measured by MTT assay. A) The survival of mock RNA transfected cells expressing Htt-25 was comparable to cells
expressing GFP alone. A slight decrease in cell survival was observed in PKCi depleted cells expressing Htt-25 when compared to GFP transfectants (*
p,0.05). B) A marked decrease in cell survival was observed in control RNA transfected cells expressing Htt-103 that was further pronounced in PKCi
depleted cells (* p,0.05). C) Survival as measured by trypan blue exclusion of U87MG cells transfected with control or siPKCiA in the presence or
absence of Htt-103. In accordance with the MTT assay, an increase in the population of dead cells was observed in control transfected U87MG cells
expressing Htt-103 which was further increased in PKCi depleted cells. D) Flow cytometric analysis of cells transfected with either the control or
siPKCi expressing Htt-103 showing an increase in the number of dead cells in PKCi depleted cells when compared to control transfected cells. Data
represents the average of three independent experiments, with error bars indicating standard deviation (** p,0.01). E) U87MG cells stably expressing
flag epitope tagged PKCi (ftPKCi) were transiently transfected with the Htt-103 expression construct for 24 hours. Survival as assessed by MTT
p38MAPK in polyQ Toxicity
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upstream of ERK). U87MG cells were either untreated or treated
with U0126 prior to transfection with the GFP control vector, Htt-
25 or Htt-103 plasmids. Twenty-four hours post-transfection, cell
survival was assessed by the MTT assay. The data presented in
figure 3B revealed that blockade of ERK recapitulated the findings
in PKCi depleted cells: the survival of cells expressing Htt-103 was
significantly compromised (Figure 3B). The survival of Htt-25
expressing cells treated with the inhibitor was comparable to that
of GFP transfectants (Figure 3B). The efficient blockade of ERK
activation in U0126 treated cells was confirmed by Western blot
analysis of cell extracts from cells transfected with Htt-103 with the
phospho-ERK specific antibody (Figure 3C). The data in
Figure 3C also revealed that the expression of the expanded
polyglutamine protein has no effect on ERK induction when
compared to GFP transfectants. Taken together, they suggest that
the status of ERK is strictly dependent on PKCi and not the
expression of the expanded polyglutamine protein.
Expression of Htt-103 is associated with induction of
p38MAPK and its pharmacological blockade rescues cells
from polyglutamine-induced toxicity
Given that the blockade of ERK signaling preferentially
sensitized Htt-103 expressing cells when compared to Htt-25
transfectants, we reasoned that the expanded polyglutamine may
be affecting stress-inducible pro-apoptotic pathways. The activa-
tion of the p38MAPK pathway in response to environmental and
genotoxic stress is well characterized [44–46] and its induction in
response to amyloid beta treatment has been well documented
[47,48]. Expanded polyglutamine proteins have recently been
shown to induce death in cell culture models (reviewed in [49]) but
the role of p38MAPK has not been investigated. To investigate the
role of this kinase, we analyzed cell extracts from control and
PKCi depleted cells expressing GFP, Htt-25 and Htt-103 by
Western blot analysis with a phospho-p38MAPK antibody. The
analysis revealed that the expression of Htt-103 resulted in a
similar increase in p38MAPK phosphorylation in both the control
and siPKCiA transfected cells. These data suggested that the status
of PKCi has no effect on expanded polyglutamine induced
p38MAPK activation (Figure 4A) and that the increased sensitivity
observed in PKCi depleted cells was a reflection of a diminished
activation of ERK. The levels of phospho-p38MAPK remained
unchanged in GFP expressing cells and were minimally affected in
Htt-25 transfectants (Figure 4A). This suggested that the activation
of p38MAPK may be the basis for the increased cell death
observed in Htt-103 expressing cells and that interfering with its
phosphorylation may rescue cells from polyglutamine-induced
toxicity. Inhibition of p38MAPK with the use of SKF86002, a
specific p38MAPK inhibitor, resulted in a significant rescue of
Htt-103 expressing U87MG control and siPKCiA transfected cells
such that their survival was comparable to Htt-25 and GFP
transfectants treated with the inhibitor (Figure 4B). Similar results
were obtained by blockade of p38MAPK with the use of
SB202190, a different p38MAPK inhibitor; its inhibition resulted
in a statistically significant increase in cell survival of PKCi
depleted cells expressing Htt-103 (Figure 4C). The efficient
blockade of p38MAPK activation in SKF86002 treated cells was
confirmed by Western analysis of cell extracts from Htt-103
expressing cells with a phospho-ATF2 antibody, a downstream
analysis revealed a modest increase in survival in PKCi transfectants when compared to the parental U87MG cells (** p,0.01). F) Western blot analysis
of triplicate cell extracts from untransfected U87MG and cells stably expressing flag-tagged PKCi with antibodies raised against PKCi and the flag
epitope tag respectively. The flag tag specific antibody detected ectopically expressed PKCi in transfected cells, which was absent in the
untransfected control cell extracts. The PKCi antibody detected endogenous and exogenous PKCi in lysates from U87MG cells and cells stably
expressing PKCi. Pan-ERK served as the loading control. MTT and trypan blue data are represented as the average of three independent experiments
performed in triplicate, with errors bars indicating standard error of the mean.
doi:10.1371/journal.pone.0002130.g002
Figure 3. PKCi-mediated ERK activation protects cells from
expanded polyglutamine-induced cytotoxicity. A) Western blot
analysis of cell extracts from control and siPKCiA transfectants with the
phospho-ERK specific antibody. The basal levels of ERK phosphoprotein
were significantly reduced in PKCi depleted cells when compared to
control RNA transfectants. Total ERK levels were assessed with the pan
ERK antibody which also served as a loading control. B) U87MG cells
were pre-treated with the MEK inhibitor U0126 for 2 hours prior to
transfection with GFP, Htt-25 and Htt-103. Cell survival was assessed by
MTT 24 hours post-transfection. Blockade of ERK in Htt-103 expressing
cells resulted in a significant reduction in cell survival when compared
to untreated Htt-103 expressing cells (* p,0.05). Data are represented
as the average of three independent experiments performed in
triplicate, with error bars indicating standard error of the mean. C)
Western blot analysis of extracts from untreated and U0126 treated
U87MG cells expressing Htt-103 with the phospho-ERK antibody
confirming the blockade of ERK phosphorylation in U0126 treated
cells. Pan-ERK was used to detect total ERK levels and actin served as a
loading control.
doi:10.1371/journal.pone.0002130.g003
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PLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2130Figure 4. Expanded polyglutamine proteins induce p38MAPK. A) Western blot analysis of extracts from control and siPKCiA transfected cells
expressing GFP, Htt-25 or Htt-103 with the phospho-38MAPK antibody showing the phosphorylation of p38MAPK in extracts from control and
siPKCiA transfected cells expressing Htt-103. Phospho-p38MAPK levels were slightly increased in extracts from cells transfected with Htt-25 when
compared to GFP transfectants. The levels of total p38MAPK remained unchanged in all extracts as assessed by Western blot analysis with the
p38MAPK antibody. Efficient depletion of PKCi was confirmed by re-probing the membrane with the PKCi specific antibody. B) and C) Control or
siPKCiA transfected cells were either left untreated or were pre-treated with p38MAPK inhibitors, SKF86002 (B) and SB202190 (C) for 2 hours prior to
transfection with GFP, Htt-25 or Htt-103. 24 hours post-transfection, cell survival was assessed by MTT which revealed an increase in survival of Htt-
103 expressing cells by treatment with SKF86002 in both control and siPKCiA transfected cells (** p,0.01). The survival of Htt-103 expressing cells
treated with SB202190 was less pronounced when compared to SKF86002 treated cells but was still statistically increased in PKCi depleted cells when
compared to the untreated counterparts (* p,0.05). D) Western blot analysis of cell extracts from cells expressing Htt-103 that were either untreated
or treated with SKF86002 with the phospho-ATF2 antibody. The analysis revealed an abrogation of ATF2 phosphorylation in Htt-103 expressing cells
treated with SKF86002. Re-probing the membrane with an ATF-2 antibody revealed no significant difference in the total levels of ATF2 protein. Actin
p38MAPK in polyQ Toxicity
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103 expressing cells treated with SKF86002 revealed that
inhibiting p38MAPK increased the survival of Htt-103 transfec-
tants in both control and PKCi depleted cells (Figure 4E). To
further dissect the relative importance of ERK and p38MAPK in
polyglutamine-induced death, we treated GFP, Htt-25 and Htt-
103 expressing U87MG cells with SKF86002 in combination with
U0126. By MTT analysis, we found that pharmacological
inhibition of p38MAPK alone or in combination with ERK
inhibition resulted in a similar and significant rescue of cells from
death associated with expression of Htt-103 (Figure 4F). These
data suggest that the induction of p38MAPK contributes to
polyglutamine-induced cytotoxicity and that whether in the
presence or absence of activated ERK, its inhibition is sufficient
to block cell death.
Full-length expanded human Ataxin-1 protein induces
cell toxicity in a p38MAPK dependent manner
To investigate whether the depletion of PKCi and p38MAPK
pathways represent a general mechanism of expanded polygluta-
mine toxicity, we transfected control or PKCi depleted cells with
an expression construct encoding the full length ataxin-1 gene
product with an expanded polyglutamine tract of 83Q (hereafter
referred to as Atx-83). The length of the polyglutamine repeat in
normal, unaffected humans is from 6 to 40 residues and mice
expressing full length ataxin-1 with 30Qs (Atx-30) show no
phenotype effects [37]; the Atx-30 expression was therefore a
suitable control for the expanded (83Q) protein in our experi-
ments. We were unable to detect expression of an ataxin-1 protein
with only 2 glutamine residues and speculate that this variant may
be unstable (data not shown). Western blot analysis of cell extracts
from Atx-30 and Atx-83 transfected cells with the phospho-
p38MAPK antibody revealed an increase in p38MAPK activation
in Atx-83 expressing cells when compared to Atx-30 and parental
U87MG cells (Figure 5A). Additionally, the ectopic expression of
Atx-30 and Atx-83 resulted in an increase in total levels of
p38MAPK as assessed by Western analysis of the same membrane
with the antibody raised against total p38MAPK (Figure 5A). An
increase in p38MAPK activation in response to ectopic expression
of Atx-83 was also observed in NIH-3T3 fibroblasts and HT4
neuroblastoma cells suggesting that its induction represents a cell
type independent mechanism of polyglutamine cytotoxicity
(Figure 5B). By MTT assay, we found that the survival of control
RNA transfected U87MG cells expressing Atx-83 was reduced
when compared to cells expressing the non-expanded Atx-30
counterpart 24 hours post-transfection (Figure 5C). The sensitivity
of cells expressing Atx-83 was significantly increased in PKCi
depleted cells; survival was reduced by approximately 20% when
compared to control RNA-transfected cells expressing an empty
vector control (Figure 5C). Pharmacological inhibition of
p38MAPK with the use of SKF86002 in Atx-83 expressing cells
recapitulated the findings in Htt-103 transfectants; a statistically
significant increase in cell survival was observed in control RNA
transfectants and was more pronounced in PKCi depleted cells
(Figure 5C). To confirm that the rescue observed in SKF86002
treated cells was attributable to blockade of p38MAPK signaling,
we transiently co-transfected U87MG cells with the Atx-30 or Atx-
83 plasmids in conjunction with constructs encoding either flag
tagged wild-type p38 alpha (wt p38) or its dominant-negative
kinase dead counterpart (KD p38). These expression constructs
have previously been used to examine the contribution of
p38MAPK signaling in cultured cells [50,51]. By MTT analysis
we found that expression of the kinase dead p38MAPK increased
survival of Htt-103 expressing cells in a similar manner to
blockade with SKF86002 suggesting that the decrease in survival is
due to activation of p38MAPK. The expression of wt p38 had no
significant impact on survival of Atx-83 expressing cells
(Figure 5D). The expression levels of Atx-30 and Atx-83 were
similar as assessed by Western blot analysis with an ataxin-1
specific antibody (Figure 5E).
Expanded polyglutamine protein induced p38MAPK in
the cerebella of SCA-1 transgenic mice
The in vivo induction of p38MAPK was examined in the
previously characterized B05 mouse model of spinocerebellar
ataxin-1 (SCA-1). In this model a human ataxin-1 cDNA with an
expanded CAG tract encoding 82 glutamines is specifically
expressed in Purkinje neurons (reviewed in [52]). The A02
transgenic strain expressing a similar construct with a non-
pathological expansion of 30 glutamines served as a control.
Western blot analysis of cerebellar extracts from aged-matched
3 month old mice with the phospho-p38MAPK antibody revealed
phosphorylation of p38MAPK in extracts from nine B05 mice (five
of which are shown in Figures 6A and B). In agreement with the
findings in cultured cells, the phosphorylation of p38MAPK in
lysates from A02 mice was lower than that detected in B05 extracts
but slightly increased when compared to lysates from nontrans-
genic controls (Figure 6A). Contrary to what was observed in
lysates from U87MG cells transfected with Atx-30 and Atx-83, re-
probing the membrane with the antibody raised against total p38
revealed that total p38MAPK levels remained unchanged in A02
and B05 lysates when compared to nontransgenic control lysates
(Figure 6A). We speculate that the induction of total p38MAPK
levels may simply represent a response of cultured cells to the
expression of Atx-30 and Atx-83. In B05 mice we observed a
significant induction in p38MAPK phosphorylation at 3 months
of age, while mice at 1 and 2 months of age show little or no
detectable p38MAPK phosphorylation (Figure 6C). This activa-
tion correlates well with the onset of behavioral and anatomical
anomalies in the mouse model of SCA-1. We examined the
localization of phosphorylated p38MAPK by immunohistochem-
istry in cerebella of 3 month old nontransgenic and B05 mice. We
found that phosphorylated p38MAPK was primarily localized to
the cytoplasm and nucleus of Purkinje neurons (Figure 6D),
showing that the increase in the levels of activated p38MAPK (as
detected by Western analysis) could be attributed to expanded
polyglutamine expression in those cells.
served as a loading control. E) Flow cytometric analysis of control and siPKCiA transfected cells expressing Htt-103 that were either left untreated or
treated with SKF86002. The survival of SKF86002 treated, Htt-103 expressing cells was significantly improved when compared to the untreated
counterparts and was comparable to the survival of GFP and Htt-25 transfectants in both the mock and PKCi depleted cells. Data is represented as
the average of three independent experiments performed in duplicate with error bars indicating standard error of the mean. F) U87MG cells
transfected with GFP, Htt-25 and Htt-103 were treated with SKF86002 in combination with U0126. Survival was assessed by MTT assay 24 hours post-
transfection. As described above, treatment of Htt-103 expressing cells with U0126 resulted in reduced viability (* p,0.05) whereas treatment with
SKF86002 alone or in combination with U0126 rescued cells from polyglutamine toxicity to a level that was similar to p38MAPK inhibition alone (**
p,0.01). Data are represented as the average of three independent experiments performed in triplicate, with error bars indicating standard error of
the mean.
doi:10.1371/journal.pone.0002130.g004
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PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2130Figure 5. Expanded ataxin-1 toxicity is mediated through induction of p38MAPK. A) Western blot analysis of duplicate cell extracts from
U87MG cells expressing Atx-30 and Atx-83 with the phospho-p38MAPK antibody. An increase in phosphorylated p38MAPK was observed in lysates
from Atx-83 expressing cells when compared to lysates from mock transfected or cells expressing Atx-30. Total levels of p38MAPK were increased in
lysates from cells transfected with either Atx-30 and Atx-83 when compared to mock transfected cells as assessed by re-probing of the membrane
with the p38MAPK antibody. Actin served as a loading control. B) HT4 and NIH-3T3 cells were transiently transfected in duplicate with the Atx-83
expression construct. Cell extracts were analyzed by western blot analysis with the phospho-p38MAPK antibody. p38MAPK activation was observed
in cell extracts from both NIH-3T3 and HT4 cells expressing Atx-83. The induction of p38MAPK was not observed in lysates from cells expressing an
empty vector control. C) Untreated or SKF86002 treated control or siPKCiA transfected cells were transfected with Atx-30 or Atx-83 for 24 hours and
cell survival was assessed by MTT. The analysis revealed a decrease in survival of Atx-83 expressing cells in control RNA transfected cells that was
significantly more pronounced by PKCi depletion. Blockade of p38MAPK increased survival of Atx-83 expressing cells in both control and siPKCi
transfectants such that it was comparable to the survival of Atx-30 expressing cells. Data represent the average of three independent experiments
performed in triplicate, with error bars indicating standard error of the mean (* p,0.05). D) U87MG cells were co-transfected with Htt-103 and either
empty vector alone or expression constructs encoding wild-type (wt p38) or dominant-negative (KD) p38MAPK alpha. 24 hours post-transfection,
cells were analyzed by MTT which revealed a statistically significant increase in survival in cells co-expressing Htt-103 and dominant-negative
p38MAPK alpha (** p,0.01). The survival of cells expressing empty vector control alone or co-expressing Htt-25 with empty vector was not
significantly different. E) Western blot analysis of extracts from Atx-30 and Atx-83 transfected cells with an ataxin-1 specific antibody revealinga
similar level of expression. Actin served as a loading control.
doi:10.1371/journal.pone.0002130.g005
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Clear evidence for the essential role of protein kinase C family
members in neuronal homeostasis has been provided by
neurodegeneration attributable to a loss of function mutation in
the PKCc gene in spinocerebellar ataxia type 14 (SCA-14, [53]).
No such genetic disorder has been mapped to the PKCi gene, but
evidence from overexpression studies indicates that PKCi can be
protective against a variety of cytotoxic insults including UV
damage and chemotherapy [38,54] and neurotoxic insults
including beta amyloid [55]. Conversely, inhibition of PKCi and
the closely related PKCf by the prostate apoptosis-response 4
(PAR-4) protein has been recently shown to increase proteolytic
processing of amyloid precursor protein [56,57] and to exacerbate
Ab accumulation and toxicity in mouse models of Alzheimer’s
disease [58,59] suggesting a role for PKCi in modulating survival.
Using specific MAP kinase inhibitors we have established that
p38MAPK is activated in expanded polyglutamine expressing cells
and that PKCi-mediated ERK activation can antagonize
polyglutamine-induced cell death in a cell culture model. Our
data are in accordance with a recent report demonstrating the
protective effects of ERK activation in expanded polyglutamine
expressing cells [19]. Based on our findings, we propose a
mechanism (schematically depicted in Figure 7) wherein
p38MAPK induction contributes significantly to the toxicity
observed in expanded polyglutamine expressing cells while ERK
activation serves to counteract its effects. The fate of cells
Figure 6. In vivo induction of p38MAPK in SCA-1 mice. A) and B)
Western blot analysis of cerebellar extracts from 3 month-old non-
transgenic, A02 and B05 mice with the phospho-p38MAPK antibody. An
increase in the protein levels of phospho-p38 was detected in the
extracts from B05 mice when compared to A02 and nontransgenic
control extracts. Total p38MAPK levels were similar as assessed by re-
probing the membrane with the p38MAPK antibody or actin. C)
Western blot analysis of cerebellar extracts from B05 mice at 1,2 and
3 months of age with the phospho-p38MAPK antibody. The analysis
revealed a detectable induction in p38MAPK activation in lysates from
mice at 3 month of age. Total levels of p38MAPK were assayed by re-
probing the membrane with the p38MAPK antibody which also served
as a loading control. D) Immunohistochemistry of mouse cerebella with
the phospho-p38MAPK antibody. Panel i) cerebellum of a B05 animal
and panel ii) cerebellum of a nontransgenic animal. Immunoreactivity
was observed in the cytoplasm and nucleus of Purkinje neurons in B05
and nontransgenic mice. Panel iii) section from a B05 animal stained
with the secondary antibody alone demonstrating the absence of
immunoreactivity by omission of the primary antibody. Scale bars
represent 25 mm.
doi:10.1371/journal.pone.0002130.g006
Figure 7. Model of polyglutamine induced toxicity. Activation
p38MAPK signaling is counteracted by PKCi-mediated ERK activation in
expanded polyglutamine expressing cells. The pharmacological block-
ade of ERK with U0126 or by PKCi depletion sensitizes cells to
polyglutamine-induced death through a mechanism of exaggerated
induction of p38MAPK (A). In contrast, inhibition of p38MAPK
phosphorylation by SKF86002 or SB202190 rescues cells from
polyglutamine toxicity (B). The blockade of both signaling pathways
in cells expressing expanded polyglutamine proteins recapitulates
blockade of p38MAPK (B) indicating a causative association between
p38MAPK induction and polyglutamine induced death.
doi:10.1371/journal.pone.0002130.g007
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determined, in part, by comparing the activation state of the two
signaling cascades. In this model the ERK cascade would generate
a pro-survival signal in response to PKCi-mediated input. The
p38MAPK cascade would generate a pro-death output specifically
in response to the expanded polyglutamine protein. If the
p38MAPK signal outweighed the ERK signal (as is the case by
expression of expanded polyglutamine proteins or by blockade of
ERK and/or PKCi signaling) the cell would respond by activating
its cell death program. In the presence of expanded polyglutamine
proteins the simultaneous blockade of both ERK and p38MAPK
signaling pathways was found to be functionally equivalent to
blockade of p38MAPK alone suggesting that the inhibition of
p38MAPK was sufficient to block cell death regardless of the
presence or absence of activated ERK (Figure 4F). To promote the
survival of neurons in neurodegenerative disorders it may
therefore suffice to block p38MAPK signaling (there may be no
added therapeutic benefit in promoting the ERK-mediated
survival signal, despite previously published evidence that ERK
activation promotes survival of polyQ-expressing PC12 cells [19]).
Consistent with our supposition that p38MAPK blockade should
be the therapeutic objective is recent evidence demonstrating that
the promotion of ERK-mediated signaling may ultimately
compromise neuronal viability ([60–62] and reviewed in [63,64]).
A recent report has implicated activated stress inducible JNK in
a cell culture model of HD [19] and its pharmacological blockade
resulted in a statistically significant but partial inhibition of cell
death [19]. Our data do not allow us to formally exclude a role for
JNK, and it is conceivable that the concerted action of both these
pathways mediate adverse effects on polyglutamine expressing
cells. Whether or not this is the case the almost complete rescue of
cell death by inhibition of p38MAPK under our experimental
design suggests a significant contribution of this kinase in
mediating toxicity.
The model presented in Figure 7 is based on data from
polyglutamine tracts in two quite different contexts (an expanded
polyglutamine tract appended to exon 1 of the huntingtin protein
and the pathogenic form of full length ataxin-1), suggesting that it
may have applicability to expanded polyglutamine proteins in
general. The activation of p38MAPK was detected in cultured
mammalian cells of different origins (glioblastoma, fibroblasts and
cells of neural lineage) and more importantly in cerebellar Purkinje
neurons of transgenic mice expressing the neuropathogenic ataxin-
1 cDNA at the age of onset of pathology (Figure 6 and [65]). In
conjunction with recent reports demonstrating p38MAPK induc-
tion in cellular [66] and animal models of Alzheimer’s disease
[67,68] and amyotrophic lateral sclerosis [69–71], our data suggest
that blockade of p38MAPK may have broad utility in delaying the
progress of neurodegenerative diseases, even those that do not
involve expanded polyglutamine proteins. Consistent with this
supposition is the finding that inhibition of p38MAPK is beneficial
in mouse models of disease [72,73] and in the suppression of
human inflammatory conditions [74–76]. Here we demonstrate
that pharmacological blockade of p38MAPK may potentially be
an efficacious intervention for the polyglutamine disorders. Such
an intervention may not only attenuate regional inflammation
(reviewed in [77]) and decrease the phosphorylation of HSP27 (a
downstream target of p38/MAPKAP 2/3 whose phosphorylation
status has been shown to modulate the cytotoxity of polyglutamine
expressing cells, [78]), but may delay or preclude the otherwise
inexorable neuronal loss that is associated with these diseases.
Other therapeutic modalities may become apparent as the
events downstream of p38 MAPK activation by polyglutamine
proteins become known. At this point it is not at all clear how
many and which of the several pathogenic mechanisms might be
affected by p38MAPK signaling. One plausible scenario is that
p38MAPK activation leads to transcriptional dysregulation
through negative effects on pivotal transcriptional regulators. For
example, the levels of the p300/CBP histone acetyltransferase
enzymes are known to be affected by expanded polyglutamine
proteins [6,79–81], and their loss correlates with reduced
expression of a set of target genes whose importance to neuronal
homeostasis is well established [79,82]. It has recently been shown
that p300 is degraded by the proteasome in response to p38MAPK
activation [83] and that partial inhibition of proteolysis may delay
the loss of p300/CBP in the SCA-1 model [84]. Consistent with
this model, inhibitors of histone deacetylases (HDACs) have been
shown to have beneficial effects in counteracting polyglutamine
protein toxicity [85–88] and recently reviewed in [89]. The
histone acetyltransferases would therefore seem promising as
downstream targets of p38MAPK, and we are currently seeking a
deeper understanding of this relationship.
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